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γδ T cells can display a plethora of immune functions, but recent studies have high-
lighted their importance, in multiple disease models, as sources of the pro-inflammatory
cytokines, IL-17A (IL-17), and IFN-γ. These are produced by distinct murine effector γδ T
cell subsets that diverge during thymic γδ T cell development. Among the multiple roles
these subsets play in peripheral tissues, a striking dichotomy has emerged at tumor sites:
whereas IFN-γ+ γδ T cells inhibit tumor cell growth, IL-17+ γδ T cells promote tumor pro-
gression and metastasis formation. In this review, we discuss the main lines of evidence,
mostly from preclinical studies in mouse models, for this functional dichotomy in cancer
immunity.We further highlight very recent advances in our understanding howmetabolic
sources and pathways can impact on the balance between IFN-γ+ and IL-17+ γδ T cells in
the tumor microenvironment, which opens a new exciting avenue to explore toward the
application of γδ T cells in cancer immunotherapy.
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Introduction
γδ T cells are unconventional T cells that express a unique T-
cell receptor (TCR) composed of γ and δ chains. Although they
are of low abundance in lymphoid organs, γδ T cells can play
key roles in the physiology and immune surveillance of many tis-
sues, as firmly demonstrated in mouse models [1]. In mice, γδ
T cell development in the thymus involves a specific sequence of
somatic rearrangement of TCR genes during ontogeny, leading to
subset-characteristic TCRγ variable region (Vγ) usage [2]. Impor-
tantly, these thymic subsets are intrinsically biased to produce
either IL-17A (IL-17) or IFN-γ as result of a complex process of
“developmental pre-programming” that involves TCR-dependent
and TCR-independent mechanisms, as we [3] and others [2, 4]
have reviewed elsewhere.
Distinct effector γδ T cell subsets can be defined based on the
expression of the TNF-receptor superfamily member, CD27 [5],
and further resolved using additional markers such as CD44 and
CD45RB [3, 6, 7]. The fate of γδ T cell progenitors is seemingly
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dictated by TCRγδ signaling, since strong TCRγδ signals inhibit
the generation of IL-17-producing γδ (γδ17) T cells while promot-
ing IFN-γ-producing γδ (γδIFN) T cell development [3, 6, 7]. The
cellular and molecular mechanisms underpinning the differentia-
tion of γδ17 versus γδIFN T cells have been recently reviewed else-
where [8].
Effector γδ T cell subsets are known to play crucial roles in
tissue homeostasis [1], autoimmunity [9], and cancer [10]. Here,
we will concentrate on cancer immunity, where γδ T cells play
crucial roles and thus represent a promising option for next-
generation immunotherapies [10, 11]. In this context, γδ T cells
share functional similarities with their αβ T cell counterparts,
such as cytotoxic functions and secretion of pro-inflammatory
cytokines. However, in contrast to αβ T cells, γδ T cells are
mostly independent on MHC-mediated presentation of mutated
antigens, although a recent study described an exception where
specific melanoma-associated antigens were recognized by human
γδ T cells in an MHC class I-restricted manner [12]. In gen-
eral, γδ T cells sense “stress-inducible” changes, conveyed either
via the TCR-γδ or NK cell receptors, like NKG2D, to become
activated and deploy rapid effector responses in transformed
tissues [13, 14].
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In the tumor microenvironment (TME), murine γδ T cells
typically belong to the Vγ1+, Vγ4+, or Vγ6+ (using the Heilig
& Tonegawa nomenclature [15]) subsets. These subpopulations
have different functional biases to produce either IL-17 or IFN-γ:
Vγ1+ T cells are IFN-γ-biased, whereas Vγ6+ T cells produce
almost exclusively IL-17, and Vγ4+ T cells contain sizeable
IL-17-producing and IFN-γ-producing sub-populations [2, 3].
This is particularly important because these two cytokines, and
thus the corresponding γδ T cell subsets, typically play opposing
roles in the TME: whereas γδIFN cells are potent antitumor type
1 cytotoxic effectors, γδ17 cells are mostly pro-tumoral, through
inducing angiogenesis, tumor cell proliferation, and recruiting
immunosuppressive cells to the TME [10]. In this review, we
discuss the current knowledge on tumor-associated γδ T cell
subsets, while integrating very recent discoveries on a striking
metabolic dichotomy between γδIFN and γδ17 T cells [16] that
define a new perspective to improve the performance of γδ T cells
in cancer immunotherapy.
Pro-tumoral functions of γδ17 cells
The TME is often conducive to IL-17 production. In fact, high lev-
els of IL-17 have been detected in the different types of tumor
in mice and humans [17, 18]. Interestingly, it has been recently
found that increased IL-17 in the LN microenvironment during
ageing leads to accumulation of γδ17 T cells, which associates with
accelerated tumor growth [19]. Two γδ17 T cell subsets can be
major sources of IL-17 at tumor sites: Vγ4+ γδ17 T cells predomi-
nate in hepatocellular carcinoma [20] and in breast tumor murine
models [21], whereas Vγ6+ γδ17 T cells are enriched in lung [22],
ovarian [23], and cervical [24] tumor mouse models (Fig. 1). Var-
ious cytokines have been associated with γδ17 T cell accumulation
in different tumor models: IL-1β in breast and lung metastasis
[21, 25], IL-6 in pancreatic cancer [26], IL-1β plus IL-23 in hepa-
tocellular carcinoma [20], IL-6/IL-23/TGF-β in fibrosarcoma and
skin carcinoma [27], and IL-1β / IL-6 /IL-7 in ovarian cancer [23]
models. These γδ17 T cell expansions and IL-17 secretion can have
three major consequences that benefit tumor progression: promo-
tion of angiogenesis, stimulation of tumor cell proliferation, and
orchestration of an immunosuppressive TME (Fig. 2). Of note,
while γδ17 T cells are rare in humans, some studies revealed that
γδ T cells can constitute a major source of IL-17 within tumor-
infiltrating lymphocytes, particularly in colorectal cancer [28, 29].
Angiogenesis and tumor cell proliferation
Wakita and colleagues proposed for the first time, in a semi-
nal paper, that γδ17 T cells supported tumor growth through
Figure 1. Opposite roles of murine γδ T cell subsets in cancer. Distinct γδ T cell subsets play an anti- (red) or pro- (blue) tumoural roles in various
experimental mouse cancer models. Vγ1+, Vγ4+ and Vγ5+ T cell subsets producing IFN-γ are protective in several skin cancers such as squamous
cell carcinoma, 3-methylcholanthrene (MCA)/ 7,12-dimethylbenz]alpha]anthracene (DMBA)-induced cutaneous tumors or B16-F0 melanoma. γδ
T cells are also overtly anti-tumoural in: (i) spontaneous B cell lymphoma in mice lacking beta 2 microglobulin (β2m) and/ or perforin (Pfn), (ii)
gastrointestinal stromal tumors due to activating mutation in the KIT proto-oncogene, via GM-CSF, and (iii) prostate adenocarcinoma in TRAMP
mice. In contrast, Vγ6+ γδ17 T cells play pro-tumor roles in Kras-induced lung cancer and Lewis lung carcinoma, as well as in ID8 ovarian cancer and
in Human papillomavirus (HPV)-induced cervical squamous cell carcinoma (SCC) models. Other IL-17-producing γδ T cells, especially Vγ4+ T cells,
are detrimental in (i) Hepa1-6 hepatocellular carcinoma, (ii) pancreatic adenocarcinoma in PDA and pancreatic intraepithelial neoplasia (PanIN)
models, and (iii) KEP breast cancer metastatic mouse model.
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Figure 2. Pleiotropic functions of γδ T cells in the TME. Pro-tumoural roles of γδ T cells (left panel in blue) include the production of IL-17 which
stimulates tumor cell proliferation, induces angiogenesis, and recruits immunosuppressive cells like myeloid-derived suppressive cells (MDSC)
that inhibit cytotoxic T lymphocytes (CTL). γδ T cells can also inhibit DC maturation and exert IL-17-independent pro-tumor roles, via galectin-
9, programmed cell death protein 1 ligand 1 (PDL-1) or IL-10, which inhibit αβ T cell responses; or through production of amphiregulin or IL-22
that promote tumour cell proliferation. Antitumoral roles of γδ T cells (right panel in red), activated through the T cell receptor (TCR) and NK cell
receptors (NKRs) to kill tumor cells upon expression of perforin and granzymes, FAS ligand (FASL) and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), as well as the cytokines tumor necrosis factor α (TNF-α) and IFN-γ. IFN-γ upregulatesMHC class I expression on tumor cells,
which enhances their recognition by cytotoxic T lymphocytes. IFN-γ also induces the differentiation of antitumor macrophages (M) and enhances
the presentation capacity of antigen-presenting cells. Additionally, γδ T cells promote the maturation of DCs via secretion of GM-CSF; promote
activation of CD8+ T cells; increase cytotoxicity of NK cells via CD137L expression; and, through IL-13 secretion, induce antibody class switching in
B cells to autoreactive antitumor IgE.
induction of angiogenesis [27]. They showed that IL-17 within
tumors was predominantly produced by γδ T cells, and in the
transplantable methylcholanthrene (MCA)-induced CMS-G4
tumor cell line model, mice lacking IL-17 showed reduced tumor
growth associated with decreased vascular density within the
tumor tissue. Conversely, the administration of IL-17 increased
the expression of pro-angiogenic factors such as vascular endothe-
lial growth factor (VEGF) and angiopoietin 2 by tumor cells [27].
Our group found that γδ17 T cells can also induce angiogen-
esis indirectly by upregulating proangiogenic factors in small
peritoneal macrophages (SPMs) that are mobilized by IL-17 to
the peritoneal cavity in the transplantable ID8 ovarian cancer
model [23]. Moreover, a more recent study showed that γδ17
T cells stimulated the formation of blood vessels in the dermis
underlying human papillomavirus-induced tumor lesions [24].
Interestingly, γδ17 T cells can also promote the formation of lung
metastases through tumor-endothelial transmigration by acting
on blood vessel permeability and upregulating the expression of
adhesion molecules such as E-selectin and VCAM-1 by endothelial
cells [30].
Importantly, γδ17 T cells, via IL-17, can also directly stimulate
tumor cell growth. IL-17 (provided by γδ17 and CD4+ Th17 cells)
is required for the initiation and progression of early pancreatic
cancer: pancreatic cells sense IL-17 in the TME through IL-17
receptors and downstream signaling leads to the acceleration of
pancreatic intraepithelial neoplasia [26].
Recruitment of immunosuppressive cells to the TME
γδ17 T cells can drive cancer progression by recruiting pro-
inflammatory or immunosuppressive cells to the tumor site
(Fig. 2). He et al. showed that IL-17 is necessary for both the
recruitment and development of myeloid-derived suppressor cells
(MDSCs) [31]. We also found that γδ17 Vγ6+ T cells mobilize pro-
inflammatory SPMs expressing high levels of IL-17RA, which in
turn support ID8 ovarian cancer cell growth [23]. γδ17 Vγ4+ T
cells also exert their pro-tumoural functions by recruiting MDSCs
in hepatocellular carcinoma, but in this case indirectly via induc-
tion of CXCL5 production by tumor cells [20]. This underpins an
interesting positive feedback loop, since IL-17-stimulated MDSCs
secrete IL-1β and IL-23 that support γδ17 Vγ4+ T cell expansion.
Of note, human γδ17 T cells have also been associated with intra-
tumor infiltration and accumulation of MDSCs in colorectal can-
cer patients [28].
γδ17 T cells also recruit neutrophils to the TME (Fig. 2), and
neutrophil abundance in metastatic breast cancer patients corre-
lates with decreased survival [32]. In pre-clinical spontaneous
breast cancer murine models, Coffelt and colleagues demon-
strated that γδ17 T cells drive the systemic expansion and polar-
ization of neutrophils towards a CD8+ T cell-suppressive phe-
notype, and thereby promote lung and LN metastasis [21, 33].
Consistently, the absence of γδ T cells or neutrophils substantially
reduced pulmonary and LN metastases. However, neutrophils can
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display pleiotropic and somewhat contradictory roles in differ-
ent cancer models. For example, our group found that tumor-
associated neutrophils can suppress γδ17 T cell responses through
induction of oxidative stress (via ROS production), to which γδ17
T cells are particularly susceptible due to very low levels of the
cellular antioxidant, glutathione [34]. Thus, the functional cross-
talks between γδ17 T cells and other immune cells, especially of
the multifaceted myeloid lineage, deserves further investigation.
Antitumor functions of γδ(IFN) T cells
Girardi et al. demonstrated, for the first time, that γδ T cells were
host-protective in transplantable squamous cell carcinoma and
methylcholanthrene (MCA)-induced or dimethylbenzanthracene
(DMBA)-induced cutaneous tumor models, since tumor growth
and progression were markedly increased in TCRδ–/– mice [35,
36]. Since then, γδ T cells have been shown to provide tumor
immunosurveillance in various other models [10, 37], also when
adoptively transferred into mice bearing B16-F0 melanomas [38]
or adenocarcinomas of the prostate (TRAMP mice) [39] (Fig. 1).
By generating BM chimeras and foetal liver reconstitutions vary-
ing only in their γδIFN T cell composition, Gao et al. showed that
mice with IFN-γ-deficient γδ T cells have higher tumor incidence
than those bearing γδIFN T cells [40]. Following this original study,
many others followed in attributing crucial antitumor roles to
γδIFN T cells [10, 37, 38], which are endowed with potent cyto-
toxic functions and orchestrate an overt antitumor TME (Fig. 2).
Cytotoxicity against tumor cells
The seminal studies by Girardi et al. focused on Vγ5+ dendritic
epidermal γδ T cells (DETCs), which are prototypic γδIFN T cells
due to thymic “developmental pre-programming” [3, 41]. DETCs
were shown to deploy potent cytotoxicity against squamous cell
carcinoma, upon engagement of their signature TCR as well as the
critical NK cell receptor, NKG2D [35, 36, 42]. Interestingly, recent
studies have shown that rapamycin, which suppresses mTOR sig-
naling, increases NKG2D expression on Vγ4+ γδ T cells, enhancing
their cytotoxicity against multiple tumor cell lines [43]. Cytotox-
icity is a common feature of all murine γδIFN T cell subsets, but
some finer differences seem to exist. For example, TCRδ–/- mice
reconstituted with Vγ4+ γδ T cells were better protected against
B16 melanoma and YAC-1 cell lymphoma cells than those recon-
stituted with Vγ1+ γδ T cells [38].
Human γδ T cells also combine IFN-γ production with cyto-
toxicity, and have been shown to kill renal cell carcinoma [44],
squamous cell carcinoma [45], colon cell carcinoma [45, 46], and
acute [47] and chronic myeloid leukemia cells [48], among vari-
ous other tumor types [49].
The cytotoxic mechanisms are multi-layered, involving the
perforin–granzyme axis, but also “death ligands,” namely FASL
and TRAIL, which engage the “death receptors” FAS (CD95) and
TRAIL [39, 48, 50, 51] (Fig. 2). Of note, human γδ T cells also
express CD16 (or Fcγ receptor III) that binds the Fc region of IgG
antibodies, thus enabling antibody-dependent cellular cytotoxic-
ity (ADCC) coupled to Granzyme production and IFN-γ secretion
[52–54].
Modulation of antitumor immunity
An important role of γδIFN T cells is to promote an antitumor TME,
for which the impact of IFN-γ on MHC class I expression makes
a key contribution. For example, tumor-infiltrating γδIFN T cells
were shown to regulate (via IFN-γ production) the expression of
MHC class I on murine B16 melanoma cells, thus promoting their
recognition by CD8+ T lymphocytes [55] (Fig. 2).
However, not all protective effects of γδ T cells in cancer immu-
nity depend on IFN-γ production. For example, Strid and col-
leagues demonstrated that DETCs promote antibody class switch-
ing to IgE, which is highly protective against chemically induced
skin carcinogenesis mouse model [56]. Moreover, DETCs cross-
communicate with epithelial cells via the production of IL-13 that
activates a very dynamic epithelial stress response in the epider-
mis in mice, which is protective against cutaneous carcinogene-
sis [57]. This host-defensive type 2 (atopic) response by murine
DETCs is deployed upon sensing of NKG2D ligands during cuta-
neous epithelial stress [58]. It is still unclear if other γδ T cell
subsets can similarly engage an IL-13/ IgE pathway in antitumor
immunity.
A recent study described a protective role for γδ T cells in a
mouse model of gastrointestinal stromal tumor through the secre-
tion of GM-CSF [59]. The authors proposed a model where tumor-
associated macrophages secreting IL-1β promoted GM-CSF pro-
duction by γδ T cells, leading to the maturation of CD103+CD11b–
DCs, which were associated with effector CD8+ T cell infiltration
within tumors. In humans, the main circulating γδ T cell subset,
Vγ9Vδ2 T cells, have been shown to promote CD8+ T cell acti-
vation based on their DC-like ability to cross-present antigens on
MHC class I and to express high levels of costimulatory molecules
upon activation [60–64].
In sum, γδ T cells can display multifaceted antitumor mech-
anisms, with type 1 cytotoxic γδIFN T cells taking center stage
(Figs. 1 and 2). The functional dichotomy between (protective)
γδIFN and (pathogenic) γδ17 T cell subsets highlights the impor-
tance of their balance in tumor immunity. In this context, we have
very recently unraveled how metabolic sources and pathways dif-
ferentially impact on γδIFN versus γδ17 T cells and their activities
in the TME [16].
Metabolic regulation of γδ T cell subsets in cancer
Until recently, the information on γδ T cell metabolism was
very scarce. By contrast, many studies on αβ T cells had shown
that metabolic pathways and metabolites regulate T cell signal-
ing, survival, differentiation, and function [65]. Metabolism is
highly dynamic in the life cycle of T cells: naïve T cells display
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a metabolic quiescent phenotype and use the available nutrients
to maximize energy production through oxidative phosphoryla-
tion (OXPHOS) in mitochondria [66]; upon activation, T cells
require a metabolic reprogramming in which they engage aerobic
glycolysis, i.e conversion of glucose into lactate, in the cytoplasm
[67]. While less efficient than OXPHOS to produce ATP, aerobic
glycolysis generates crucial metabolic components, like glucose
and lactate, important for cell growth and proliferation [68]. Fur-
ther changes in metabolism also occur during the differentiation
of memory T cells [69, 70], which primarily use OXPHOS, but
undergo a glycolytic switch when deploying their rapid effector
functions [71–73]. Our recent data demonstrate that γδIFN and
γδ17 T cells also differentially engage in aerobic glycolysis versus
mitochondrial respiration [16].
Metabolic dichotomy in γδ T cell subsets
We investigated the metabolic profile of γδ T cell subsets using
a newly developed protocol, SCENITHTM (Single Cell mEtabolism
by profilIng Translation inHibition), which is a simple method for
deciphering the complex energy systems employed by immune
cells [74]. This method uses the drug puromycin, whose incor-
poration into nascent proteins is a highly reliable readout of pro-
tein synthesis levels. The addition of specific chemical inhibitors
allows the estimation of glucose dependence, mitochondrial
dependence, glycolytic capacity, and fatty acid and amino acid
oxidation capacity. Flow cytometry analysis, using a fluorescent
antibody against puromycin, defines simultaneously the ex vivo
phenotype and the energy metabolism of multiple cell popula-
tions in parallel [74]. Using this methodology, we found that
γδ T cell subsets exhibit clearly distinct metabolic profiles that
are imprinted during γδ thymic development and maintained
in peripheral lymphoid organs and within tumors [16]. On one
hand, γδIFN T cells are highly glycolytic, consistent with reports
showing that glycolysis is required for the production of IFN-γ by
NK cells [75] and CD8+ T cells [76]. On the other hand, γδ17 T
cells have higher mitochondrial mass (and membrane potential)
and strongly rely on OXPHOS [16], similarly to CD4+ Th17 cells
[77]. We found this dichotomy in γδ T cell subsets to have a tran-
scriptional basis, including the segregation of two master regula-
tors: Nrf1, which orchestrates mitochondrial DNA transcription,
was enriched in γδ17 T cells; and Myc, which controls glycolysis,
was highly overexpressed in γδIFN T cells [16].
Metabolic modulation of γδ T cell activities in the
tumor microenvironment
It is well known that tumors adopt characteristics, including
selected metabolic advantages linked to intense proliferation,
that promote T cell hyporesponsiveness or dysfunction to escape
immunity [78]. Tumor-infiltrating immune cells can be shaped
by nutrient availability in the TME. For example, glycolysis
has been shown to regulate IFN-γ production in T cells [79];
and antibody-mediated blockade of the PD-1/PD-L1 immune
checkpoint restored glycolytic and effector functions of tumor-
infiltrating T cells [80]. While performing aerobic glycolysis
(“Warburg effect”), tumor masses heavily consume glucose, which
deprives T cells and alters their metabolism and functionalities;
thus, metabolic competition in the TME is a driver of cancer pro-
gression [80]. Consistently, resistance to adoptive T cell therapy is
observed in patients with an increased tumor glycolysis [81]. Fur-
thermore, it has been shown that high levels of lactate in the TME
lead to diminished antitumor immunity by increasing the apop-
tosis of naïve T cells and inhibiting effector T cell functions [82,
83]. Importantly, amino acid restriction such as serine, glutamine
or glycine deprivation also leads to an impaired function of CD8+
T cells and NK cells [84–86].
We have addressed the impact of the metabolic differences
between effector γδ T cell subsets on their activities in the TME,
particularly upon adoptive cell transfer. Given the high(er) gly-
colytic activity of γδIFN T cells, we explored the effect of glu-
cose supplementation on their antitumor functions in vitro and
in vivo. We found high (10-fold higher concentration of) glucose
to enhance γδIFN cell proliferation, IFN-γ production, and antitu-
mor cytotoxicity in vitro [16]. We did not consider injecting glu-
cose directly into tumors given that it would likely benefit cancer
proliferation progression [80]. Instead, we provided it to γδIFN
T cells during a short (5 h) incubation before adoptive transfer
(intra-tumoural injection); this resulted in a substantial reduction
in breast tumor growth in vivo (Fig. 3).
By contrast, high glucose was detrimental to γδ17 T cell pro-
liferation, as well as to their generation in fetal thymic organ
cultures [16]. We therefore questioned which other metabolic
resources could fuel γδ17 T cells and their activities in the TME.
We found that lipids, including palmitate and cholesterol, are
preferentially uptaken by γδ17 T cells, which become significantly
expanded in tumors from high-fat diet (HFD)-treated obese mice
(Fig. 3). Consistent with this, short-term (5h) cholesterol treat-
ment in vitro leads to increased proliferation of γδ17 T cells and,
upon adoptive transfer, cholesterol-treated γδ17 T cells substan-
tially increased (compared to controls) breast tumor growth in
vivo (Fig. 3). These data, suggesting that a lipid-rich environment
boosts γδ17 T cells to support tumor growth, provide a new mech-
anism to the body of evidence linking obesity and cancer [87],
including via immunometabolism [88, 89].
In sum, we propose that the relative abundance of glucose ver-
sus lipids is a key determinant of the balance between protective
γδIFN T cells and pathogenic γδ17 T cells in the TME.
Conclusions and implications for human disease
Although there are additional pro- versus antitumor mechanisms
deployed by γδ T cells (Fig. 2; reviewed in [10]), here we focused
on those contributed by γδIFN and γδ17 T cells. The concept of
a functional dichotomy among γδ T cell subsets in tumor immu-
nity may have important implications for development of γδ T
cell-based cancer immunotherapies. On that road, an outstanding
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Figure 3. Distinct metabolic cues control γδ T cell subset expansion and functions in the TME. (A) γδIFN T cells uptake more glucose and employ
aerobic glycolysis. γδIFN T cells supplemented with high dose of glucose exhibit increased (i) proliferation, (ii) Tbet expression, (iii) IFN-γ production
and (iv) killing capacity against cancer cells. Consequently, the adoptive transfer of glucose-”boosted” γδIFN T cells substantially reduces tumor
growth. (B) γδ17 T cells display high lipid uptake and intracellular lipid storage; and engage mitochondrial oxidative metabolism. γδ17 T cells are
expanded in lipid-rich environments such as in tumor-bearing obese mice fed with high-fat diet (HFD) leading to increase tumor growth. Likewise,
cholesterol supplementation promotes γδ17 T cell proliferation and increases tumor growth after adoptive transfer.
question to resolve using preclinical models is how the balance
between γδIFN and γδ17 T cells is regulated, particularly in the
TME, toward promoting antitumor immunity. Our most recent
research suggests that metabolism may provide some answers,
namely by limiting lipids in the TME; and favoring aerobic gly-
colysis in γδ T cell-based adoptive cell therapy (ACT) products/
strategies.
We believe that increased understanding of tumor and immune
cell metabolism may be a powerful tool for the development of
next-generation immunotherapies. Targeting the metabolism of
immune cells through the modulation of key metabolic pathways
and/or dietary interventions in order to enhance their antitu-
mor functions may improve cancer treatment [90]. An interest-
ing avenue to explore within immunometabolism is the impact
of different amino acids, since the TME also creates competi-
tion between tumor and T cells for essential amino acids. For
example, arginine is depleted by several tumors, which leads to
inhibition of T cell activation and an immunosuppressive envi-
ronment [91, 92]. Thus, optimizing arginine concentrations has
a direct impact on the metabolism and survival of T cells [92];
and one may consider providing additional arginine to cancer
patients with reduced plasma arginine levels. Another example
is glutamine, as glutaminase activity, which converts glutamine
to glutamate, is required to promote Th1 and cytotoxic CD8+ T
cell functions [93]. Finally, it has also been shown tumor cells
express IDO, an enzyme that depletes tryptophan and thus inhibits
T cell proliferation [94]. Interestingly, it has been recently shown
that IDO inhibitors enhanced human γδ T cell cytotoxicity against
pancreatic ductal adenocarcinoma [95]. Clinical trials with IDO
inhibitors in advanced solid tumors are ongoing.
We find the context of ACT particularly interesting to mod-
ulate T-cell metabolism without having undesired effects on
tumor cells. For example, modulating activated T cells to have
memory-like metabolism, weighted toward oxidative phosphory-
lation (OXPHOS) and fatty acid oxidation [90], or supplement-
ing with high doses of glucose to increase the cytotoxic activ-
ity of Th1, CD8+ or γδ T cells, may greatly improve antitumor
responses in vivo (upon ACT). Thus, enhancing “metabolic fit-
ness” of effector T cells with metabolic resources or pharmaco-
logic agents targeting key metabolic pathways may improve the
clinical efficacy of T cell-based therapies. Like glucose supplemen-
tation, the addition of specific amino acids to expansion protocols
for ACT or even as dietary supplement may also regulate γδ T cell
(subset) functions in the TME. This hypothesis deserves further
n investigation.
It is of interest to combine metabolic modulation with immune
checkpoint blockade to improve cancer treatment. In fact, both
CTLA-4 and PD-1 inhibit T-cell activation via suppression of
metabolic activity, including the downregulation of AKT phos-
phorylation, and decreased glucose and amino acid uptake
[96, 97]. On the other hand, CTLA-4 and PD-1 also interfere
with CD28 signaling [98], which is known to sustain glycolysis
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and to prime mitochondria during T cell activation [99]. Inter-
estingly, it has been recently shown that in vivo triggering of 4-
1BB costimulation, in combination with PD-1 blockade, results
in robust antitumor immunity in a B16 melanoma model [100].
Thus, metabolic modulation and immune checkpoint blockade
may constitute a promising combination to increase the efficacy
of cancer immunotherapy.
Although not detailed in this review, another major factor
to consider is the microbiome, based on a very interesting link
recently uncovered between commensal microbiota and pro-
tumoural γδ17 T cells in mouse models of lung cancer. The bac-
teria were shown to induce the production of IL-1β and IL-23 by
myeloid cells, which triggered high proliferation and activation
of Vγ6+Vδ1+ tissue-resident γδ17 T cells that supported tumor
growth [22].
Pre-clinical models are also extremely valuable to dissect the
cellular crosstalks that may control the balance between tumor-
infiltrating γδIFN and γδ17 T cells. In this regard, we have demon-
strated that neutrophils can suppress γδ17 T cell responses, while
not affecting γδIFN T cells, through ROS-mediated oxidative stress
[34]. Other positive or negative regulators of γδ T cell subsets
in the TME, including regulatory T cells [101], should be better
defined in future research.
Ultimately, one should consider the relevance of such findings
on mouse γδ T cells to human cancer, particularly as the corre-
spondence between murine and human γδ T cell subsets is not
straightforward. Namely, the Vγ-based definition of murine γδ
T cell subsets does not apply to humans, where the main sub-
populations are defined by the Vδ (segment) usage of their TCR
[102]. Thus, in humans, Vδ1+ T cells are enriched within healthy
(as well as malignant) tissues, whereas Vδ2+ T cells (mostly
Vγ9+) predominate in the peripheral blood [14]. Both subsets
have been clearly implicated in cancer immunity [10, 11, 103],
especially given their very strong cytotoxic type 1 (γδIFN) biases
[10, 104]. In fact, γδ17 T cells are much less frequent in humans
than in mice, and the presence of human γδ17 T cells in cancer is
somewhat controversial. While Wu and colleagues reported that
human γδ T cells are the major cellular source of IL-17 in col-
orectal cancer [28], a more recent study demonstrated by using
three different flow cytometry gating strategies that the major-
ity of IL-17-producing leukocytes in colorectal cancer were CD3+
but not Vδ1+ or Vδ2+ T cells, suggesting they are mostly Th17
cells [29]. Nonetheless, γδ17 T cell infiltration was shown to cor-
relate with poor survival in gallbladder cancer in humans, in
sharp contrast with γδIFN T cells [105]. Thus, the balance between
γδIFN and γδ17 T cells may be informative also in human can-
cer, although its value as a potential biomarker remains to be
established.
Acknowledgments: We thank Sofia Mensurado and Karine Serre
for helpful discussions on this topic. Our work is supported
by “la Caixa” Foundation’s Health Research Program, project
HR18-00069; PAC-PRECISE LISBOA-01-0145-FEDER-016394, co-
funded by FEDER (POR Lisboa 2020) and Fundação para a
Ciência e a Tecnologia (Portugal); and N.L. received an EMBO
longterm fellowship (ALTF 752–2018).
Author contributions: N.L. and B.S.-S. conceived and wrote the
manuscript.
Conflicts of interest: B.S.-S. is co-founder and shareholder of
Lymphact S.A., a start-up company acquired by GammaDelta
Therapeutics (London, UK). N.L. declared no commercial or finan-
cial conflicts of interest.
References
1 Ribot, J. C., Lopes, N. and Silva-Santos, B., γδ T cells in tissue physiology
and surveillance. Nat. Rev. Immunol. 2020. (in press).
2 Prinz, I., Silva-Santos, B. and Pennington, D. J., Functional development
of gammadelta T cells. Eur. J. Immunol. 2013. 43: 1988–1994.
3 Munoz-Ruiz, M., Sumaria, N., Pennington, D. J. and Silva-Santos,
B., Thymic determinants of gammadelta T cell differentiation. Trends
Immunol. 2017. 38: 336–344.
4 Sumaria, N., Martin, S. and Pennington, D. J., Developmental origins of
murine gammadelta T-cell subsets. Immunology 2019. 156: 299–304.
5 Ribot, J. C., deBarros, A., Pang, D. J., Neves, J. F., Peperzak, V., Roberts,
S. J., Girardi, M. et al., CD27 is a thymic determinant of the balance
between interferon-gamma- and interleukin 17-producing gammadelta
T cell subsets. Nat. Immunol. 2009. 10: 427–436.
6 Sumaria, N., Grandjean, C. L., Silva-Santos, B. and Pennington, D. J.,
Strong TCRgammadelta signaling prohibits thymic development of IL-
17A-secreting gammadelta T cells. Cell Rep. 2017. 19: 2469–2476.
7 Munoz-Ruiz, M., Ribot, J. C., Grosso, A. R., Goncalves-Sousa, N., Pam-
plona, A., Pennington, D. J., Regueiro, J. R. et al., TCR signal strength con-
trols thymic differentiation of discrete proinflammatory gammadelta T
cell subsets. Nat. Immunol. 2016. 17: 721–727.
8 Fiala, G. J., Gomes A.Q. and Silva-Santos, B., From thymus to periphery:
molecular basis of effector γδ T cell differentiation. Immunol. Rev. 2020.
(in press).
9 Papotto, P. H., Ribot, J. C. and Silva-Santos, B., IL-17(+) gammadelta
T cells as kick-starters of inflammation. Nat. Immunol. 2017. 18: 604–
611.
10 Silva-Santos, B., Mensurado, S. and Coffelt, S. B., gammadelta T cells:
pleiotropic immune effectors with therapeutic potential in cancer. Nat.
Rev. Cancer 2019. 19: 392–404.
11 Sebestyen, Z.,Prinz, I.,Dechanet-Merville, J.,Silva-Santos, B. and Kuball,
J., Translating gammadelta (gammadelta) T cells and their receptors into
cancer cell therapies. Nat. Rev. Drug Discov. 2020. 19: 169–184.
12 Benveniste, P. M., Roy, S., Nakatsugawa, M., Chen, E. L. Y., Nguyen, L.,
Millar, D. G.,Ohashi, P. S. et al., Generation andmolecular recognition of
melanoma-associated antigen-specific human gammadelta T cells. Sci.
Immunol. 2018. 3: 333–336.
13 Hayday, A. C., Gammadelta T cells and the lymphoid stress-surveillance
response. Immunity 2009. 31: 184–196.
14 Silva-Santos, B., Serre, K. and Norell, H., gammadelta T cells in cancer.
Nat. Rev. Immunol. 2015. 15: 683–691.
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
24 Noëlla Lopes and Bruno Silva-Santos Eur. J. Immunol. 2021. 51: 17–26
15 Heilig, J. S. and Tonegawa, S., Diversity of murine gamma genes and
expression in fetal and adult T lymphocytes. Nature 1986. 322: 836–
840.
16 Lopes, N.,McIntyre, C.,Martin, S., Raverdeau, M., Sumaria, N., Kohlgru-
ber, AC., Fiala, G. et al., Distinct metabolic programmes established in
the thymus control the effector functions of γδ T cell subsets in tumour
microenvironments. Nat. Immunol. 2020. (In press).
17 Kato, T., Furumoto, H., Ogura, T., Onishi, Y., Irahara, M., Yamano, S.,
Kamada, M. et al., Expression of IL-17 mRNA in ovarian cancer. Biochem.
Biophys. Res. Commun. 2001. 282: 735–738.
18 Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A.,
McAllister, F., Hishinuma, T. et al., IL-17 enhances the net angiogenic
activity and in vivo growth of human non-small cell lung cancer in SCID
mice through promoting CXCR-2-dependent angiogenesis. J. Immunol.
2005. 175: 6177–6189.
19 Chen, H. C., Eling, N.,Martinez-Jimenez, C. P., O’Brien, L. M., Carbonaro,
V., Marioni, J. C., Odom, D. T. et al., IL-7-dependent compositional
changes within the gammadelta T cell pool in lymph nodes during age-
ing lead to an unbalanced anti-tumour response. EMBO Rep. 2019. 20:
e47379.
20 Ma, S.,Cheng, Q.,Cai, Y.,Gong, H.,Wu, Y.,Yu, X., Shi, L. et al., IL-17A pro-
duced by gammadelta T cells promotes tumor growth in hepatocellular
carcinoma. Cancer Res. 2014. 74: 1969–1982.
21 Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau,
C. S., Verstegen, N. J. M. et al., IL-17-producing gammadelta T cells and
neutrophils conspire to promote breast cancer metastasis. Nature 2015.
522: 345–348.
22 Jin, C., Lagoudas, G. K., Zhao, C., Bullman, S., Bhutkar, A., Hu, B., Ameh,
S. et al., Commensal microbiota promote lung cancer development via
gammadelta T cells. Cell 2019. 176: 998–1013 e1016.
23 Rei, M., Goncalves-Sousa, N., Lanca, T., Thompson, R. G.,Mensurado, S.,
Balkwill, F. R.,Kulbe, H. et al.,Murine CD27(−) Vgamma6(+) gammadelta
T cells producing IL-17A promote ovarian cancer growth via mobiliza-
tion of protumor small peritoneal macrophages. Proc. Natl. Acad. Sci. U. S.
A. 2014. 111: E3562–3570.
24 Van Hede, D., Polese, B., Humblet, C., Wilharm, A., Renoux, V., Dortu,
E., de Leval, L. et al., Human papillomavirus oncoproteins induce a
reorganization of epithelial-associated gammadelta T cells promot-
ing tumor formation. Proc. Natl. Acad. Sci. U. S. A. 2017. 114: E9056–
E9065.
25 Carmi, Y., Rinott, G., Dotan, S., Elkabets, M., Rider, P., Voronov, E. and
Apte, R.N.,Microenvironment-derived IL-1 and IL-17 interact in the con-
trol of lung metastasis. J. Immunol. 2011. 186: 3462–3471.
26 McAllister, F.,Bailey, J.M.,Alsina, J.,Nirschl, C. J.,Sharma, R., Fan,H.,Rat-
tigan, Y. et al., Oncogenic Kras activates a hematopoietic-to-epithelial
IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 2014.
25: 621–637.
27 Wakita, D., Sumida, K., Iwakura, Y.,Nishikawa, H.,Ohkuri, T., Chamoto,
K.,Kitamura, H. et al., Tumor-infiltrating IL-17-producing gammadelta T
cells support the progression of tumor by promoting angiogenesis. Eur.
J. Immunol. 2010. 40: 1927–1937.
28 Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z. et al., gam-
madeltaT17 cells promote the accumulation and expansion of myeloid-
derived suppressor cells in human colorectal cancer. Immunity 2014. 40:
785–800.
29 Meraviglia, S., Lo Presti, E., Tosolini, M., La Mendola, C., Orlando, V.,
Todaro, M., Catalano, V. et al., eDistinctive features of tumor-infiltrating
gammadelta T lymphocytes in human colorectal cancer.Oncoimmunology
2017. 6: e1347742.
30 Kulig, P.,Burkhard, S.,Mikita-Geoffroy, J.,Croxford, A. L.,Hovelmeyer,N.,
Gyulveszi, G., Gorzelanny, C. et al., IL17A-mediated endothelial breach
promotes metastasis formation. Cancer Immunol. Res. 2016. 4: 26–32.
31 He, D., Li, H., Yusuf, N., Elmets, C. A., Li, J.,Mountz, J. D. and Xu, H., IL-17
promotes tumor development through the induction of tumor promot-
ing microenvironments at tumor sites and myeloid-derived suppressor
cells. J. Immunol. 2010. 184: 2281–2288.
32 Azab, B., Bhatt, V. R., Phookan, J., Murukutla, S., Kohn, N., Terjanian, T.
and Widmann, W. D., Usefulness of the neutrophil-to-lymphocyte ratio
in predicting short- and long-term mortality in breast cancer patients.
Ann. Surg. Oncol. 2012. 19: 217–224.
33 Benevides, L., da Fonseca, D. M.,Donate, P. B., Tiezzi, D. G.,De Carvalho,
D. D., de Andrade, J. M., Martins, G. A. et al., IL17 promotes mammary
tumor progression by changing the behavior of tumor cells and eliciting
tumorigenic neutrophils recruitment. Cancer Res. 2015. 75: 3788–3799.
34 Mensurado, S., Rei, M., Lanca, T., Ioannou, M., Goncalves-Sousa, N.,
Kubo, H., Malissen, M. et al., Tumor-associated neutrophils suppress
pro-tumoral IL-17+ gammadelta T cells through induction of oxidative
stress. PLoS Biol. 2018. 16: e2004990.
35 Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J.,
Tigelaar, R. E. et al., The distinct contributions of murine T cell recep-
tor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of
chemically induced skin cancer. J. Exp. Med. 2003. 198: 747–755.
36 Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler,
R., Hobby, P. et al., Regulation of cutaneous malignancy by gammadelta
T cells. Science 2001. 294: 605–609.
37 Street, S. E.,Hayakawa, Y.,Zhan, Y., Lew, A.M.,MacGregor, D., Jamieson,
A. M.,Diefenbach, A. et al., Innate immune surveillance of spontaneous
B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp.
Med. 2004. 199: 879–884.
38 He,W.,Hao, J.,Dong, S.,Gao, Y., Tao, J., Chi, H., Flavell, R. et al., Naturally
activated V gamma 4 gamma delta T cells play a protective role in tumor
immunity through expression of eomesodermin. J. Immunol. 2010. 185:
126–133.
39 Liu, Z., Eltoum, I. E.,Guo, B.,Beck, B. H.,Cloud, G. A. and Lopez, R. D., Pro-
tective immunosurveillance and therapeutic antitumor activity of gam-
madelta T cells demonstrated in a mouse model of prostate cancer. J.
Immunol. 2008. 180: 6044–6053.
40 Gao, Y.,Yang,W., Pan,M., Scully, E.,Girardi, M.,Augenlicht, L. H.,Craft, J.
et al., Gamma delta T cells provide an early source of interferon gamma
in tumor immunity. J. Exp. Med. 2003. 198: 433–442.
41 Turchinovich, G. andHayday,A. C., Skint-1 identifies a commonmolecu-
larmechanism for the development of interferon-gamma-secreting ver-
sus interleukin-17-secreting gammadelta T cells. Immunity 2011. 35: 59–
68.
42 Strid, J., Roberts, S. J., Filler, R. B., Lewis, J. M., Kwong, B. Y., Schpero, W.,
Kaplan, D. H. et al., Acute upregulation of an NKG2D ligand promotes
rapid reorganization of a local immune compartment with pleiotropic
effects on carcinogenesis. Nat. Immunol. 2008. 9: 146–154.
43 Cao, G.,Wang, Q., Li, G.,Meng, Z., Liu, H.,Tong, J.,Huang,W. et al.,mTOR
inhibition potentiates cytotoxicity of Vgamma4 gammadelta T cells via
up-regulatingNKG2DandTNF-alpha. J. Leukoc. Biol. 2016.100: 1181–1189.
44 Viey, E., Fromont, G., Escudier, B., Morel, Y., Da Rocha, S., Chouaib, S.
and Caignard, A., Phosphostim-activated gamma delta T cells kill autol-
ogous metastatic renal cell carcinoma. J. Immunol. 2005. 174: 1338–1347.
45 Alexander, A. A., Maniar, A., Cummings, J. S., Hebbeler, A. M., Schulze,
D. H., Gastman, B. R., Pauza, C. D. et al., Isopentenyl pyrophosphate-
activated CD56+ {gamma}{delta} T lymphocytes display potent
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
Eur. J. Immunol. 2021. 51: 17–26 HIGHLIGHTS 25
antitumor activity toward human squamous cell carcinoma. Clin.
Cancer Res. 2008. 14: 4232–4240.
46 Todaro, M., D’Asaro, M., Caccamo, N., Iovino, F., Francipane, M. G., Mer-
aviglia, S.,Orlando, V. et al., Efficient killing of human colon cancer stem
cells by gammadelta T lymphocytes. J. Immunol. 2009. 182: 7287–7296.
47 Gertner-Dardenne, J., Castellano, R.,Mamessier, E., Garbit, S., Kochbati,
E., Etienne, A., Charbonnier, A. et al., Human Vgamma9Vdelta2 T cells
specifically recognize and kill acute myeloid leukemic blasts. J. Immunol.
2012. 188: 4701–4708.
48 D’Asaro,M.,LaMendola, C.,Di Liberto, D.,Orlando, V.,Todaro,M.,Spina,
M.,Guggino, G. et al., V gamma 9V delta 2 T lymphocytes efficiently rec-
ognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-
resistant chronic myelogenous leukemia cells. J. Immunol. 2010. 184:
3260–3268.
49 Lo Presti, E., Dieli, F. and Meraviglia, S., Tumor-infiltrating gammadelta
T lymphocytes: pathogenic role, clinical significance, and differential
programing in the tumor microenvironment. Front. Immunol. 2014. 5:
607.
50 Pennington, D. J., Vermijlen, D., Wise, E. L., Clarke, S. L., Tigelaar, R. E.
and Hayday, A. C., The integration of conventional and unconventional
T cells that characterizes cell-mediated responses. Adv. Immunol. 2005.
87: 27–59.
51 Li, Z.,Xu, Q.,Peng, H.,Cheng, R.,Sun, Z. and Ye, Z., IFN-gamma enhances
HOS and U2OS cell lines susceptibility to gammadelta T cell-mediated
killing through the Fas/Fas ligand pathway. Int. Immunopharmacol. 2011.
11: 496–503.
52 Couzi, L., Pitard, V., Sicard, X., Garrigue, I., Hawchar, O., Merville, P.,
Moreau, J. F. et al., Antibody-dependent anti-cytomegalovirus activity
of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood
2012. 119: 1418–1427.
53 Gertner-Dardenne, J., Bonnafous, C., Bezombes, C., Capietto, A. H.,
Scaglione,V., Ingoure, S.,Cendron,D. et al., Bromohydrin pyrophosphate
enhances antibody-dependent cell-mediated cytotoxicity induced by
therapeutic antibodies. Blood 2009. 113: 4875–4884.
54 Schiller, C. B., Braciak, T. A., Fenn, N. C., Seidel, U. J., Roskopf, C.
C., Wildenhain, S., Honegger, A. et al., CD19-specific triplebody SPM-1
engagesNKand gammadelta T cells for rapid and efficient lysis ofmalig-
nant B-lymphoid cells. Oncotarget 2016. 7: 83392–83408.
55 Riond, J., Rodriguez, S.,Nicolau, M. L., al Saati, T. and Gairin, J. E., In vivo
major histocompatibility complex class I (MHCI) expression onMHCIlow
tumor cells is regulated by gammadelta T and NK cells during the early
steps of tumor growth. Cancer Immun. 2009. 9: 10.
56 Crawford, G., Hayes, M. D., Seoane, R. C., Ward, S., Dalessandri, T., Lai,
C.,Healy, E. et al., Epithelial damage and tissue gammadelta T cells pro-
mote a unique tumor-protective IgE response. Nat. Immunol. 2018. 19:
859–870.
57 Dalessandri, T., Crawford, G., Hayes, M., Castro Seoane, R. and Strid,
J., IL-13 from intraepithelial lymphocytes regulates tissue homeostasis
and protects against carcinogenesis in the skin. Nat. Commun. 2016. 7:
12080.
58 Strid, J.,Sobolev,O.,Zafirova, B.,Polic, B. andHayday,A., The intraepithe-
lial T cell response to NKG2D-ligands links lymphoid stress surveillance
to atopy. Science 2011. 334: 1293–1297.
59 Medina, B. D., Liu, M., Vitiello, G. A., Seifert, A. M., Zeng, S., Bowler, T.,
Zhang, J. Q. et al., Oncogenic kinase inhibition limits Batf3-dependent
dendritic cell development and antitumor immunity. J. Exp. Med. 2019.
216: 1359–1376.
60 Brandes, M., Willimann, K. and Moser, B., Professional antigen-
presentation function by human gammadelta T Cells. Science 2005. 309:
264–268.
61 Altvater, B., Pscherer, S., Landmeier, S., Kailayangiri, S., Savoldo, B.,
Juergens, H. and Rossig, C., Activated human gammadelta T cells
induce peptide-specific CD8+ T-cell responses to tumor-associated self-
antigens. Cancer Immunol. Immunother. 2012. 61: 385–396.
62 Mao, C.,Mou, X.,Zhou, Y.,Yuan, G.,Xu, C.,Liu, H.,Zheng, T. et al., Tumor-
activated TCRgammadelta(+) T cells from gastric cancer patients induce
the antitumor immune response of TCRalphabeta(+) T cells via their
antigen-presenting cell-like effects. J. Immunol. Res. 2014. 2014: 593562.
63 Himoudi, N., Morgenstern, D. A., Yan, M., Vernay, B., Saraiva, L., Wu, Y.,
Cohen, C. J. et al., Human gammadelta T lymphocytes are licensed for
professional antigen presentation by interaction with opsonized target
cells. J. Immunol. 2012. 188: 1708–1716.
64 Muto, M., Baghdadi, M., Maekawa, R., Wada, H. and Seino, K., Myeloid
molecular characteristics of human gammadelta T cells support
their acquisition of tumor antigen-presenting capacity. Cancer Immunol.
Immunother. 2015. 64: 941–949.
65 Almeida, L., Lochner, M., Berod, L. and Sparwasser, T., Metabolic path-
ways in T cell activation and lineage differentiation. Semin. Immunol.
2016. 28: 514–524.
66 van derWindt, G. J. and Pearce, E. L.,Metabolic switching and fuel choice
during T-cell differentiation and memory development. Immunol. Rev.
2012. 249: 27–42.
67 Geltink, R. I. K.,Kyle, R. L. and Pearce, E. L., Unraveling the complex inter-
play between T cell metabolism and function. Annu. Rev. Immunol. 2018.
36: 461–488.
68 Vander Heiden, M. G., Cantley, L. C. and Thompson, C. B., Understand-
ing the Warburg effect: the metabolic requirements of cell proliferation.
Science 2009. 324: 1029–1033.
69 Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bach-
mann, M. F., Larsen, C. P. et al., mTOR regulates memory CD8 T-cell dif-
ferentiation. Nature 2009. 460: 108–112.
70 Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.
S., Jones, R. G. et al., Enhancing CD8 T-cell memory by modulating fatty
acid metabolism. Nature 2009. 460: 103–107.
71 van der Windt, G. J., Everts, B., Chang, C. H., Curtis, J. D., Freitas, T. C.,
Amiel, E., Pearce, E. J. et al., Mitochondrial respiratory capacity is a crit-
ical regulator of CD8+ T cell memory development. Immunity 2012. 36:
68–78.
72 van der Windt, G. J., O’Sullivan, D., Everts, B., Huang, S. C., Buck, M. D.,
Curtis, J. D., Chang, C. H. et al., CD8 memory T cells have a bioenergetic
advantage that underlies their rapid recall ability. Proc. Natl. Acad. Sci. U.
S. A. 2013. 110: 14336–14341.
73 Gubser, P. M., Bantug, G. R., Razik, L., Fischer, M., Dimeloe, S., Hoenger,
G., Durovic, B. et al., Rapid effector function of memory CD8+ T cells
requires an immediate-early glycolytic switch. Nat. Immunol. 2013. 14:
1064–1072.
74 Argüello, R. J., Combes, A.J., Char, R., Gigan, JP., Baaziz, A.I., Bousiquot,
E., Camosseto, V. et al., SCENITH: A flow cytometry based method for
functional profiling energy metabolism with single cell resolution. Cell
Metabolism 2020. (in press).
75 Donnelly, R. P., Loftus, R. M., Keating, S. E., Liou, K. T., Biron, C. A., Gar-
diner, C. M. and Finlay, D. K., mTORC1-dependent metabolic reprogram-
ming is a prerequisite for NK cell effector function. J. Immunol. 2014. 193:
4477–4484.
76 Cham, C. M. and Gajewski, T. F., Glucose availability regulates IFN-
gamma production and p70S6 kinase activation in CD8+ effector T cells.
J. Immunol. 2005. 174: 4670–4677.
77 Shin, B., Benavides, G. A., Geng, J., Koralov, S. B., Hu, H., Darley-Usmar,
V. M. and Harrington, L. E., Mitochondrial oxidative phosphorylation
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
26 Noëlla Lopes and Bruno Silva-Santos Eur. J. Immunol. 2021. 51: 17–26
regulates the fate decision between pathogenic Th17 and regulatory T
cells. Cell Rep. 2020. 30: 1898–1909 e1894.
78 O’Sullivan, D., Sanin, D. E., Pearce, E. J. and Pearce, E. L., Metabolic inter-
ventions in the immune response to cancer. Nat. Rev. Immunol. 2019. 19:
324–335.
79 Chang, C. H., Curtis, J. D., Maggi, L. B., Jr., Faubert, B., Villarino, A. V.,
O’Sullivan, D., Huang, S. C. et al., Posttranscriptional control of T cell
effector function by aerobic glycolysis. Cell 2013. 153: 1239–1251.
80 Chang, C. H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D.,
Chen, Q. et al., Metabolic competition in the tumor microenvironment
is a driver of cancer progression. Cell 2015. 162: 1229–1241.
81 Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C.,
Williams, L. J. et al., Increased tumor glycolysis characterizes immune
resistance to adoptive T cell therapy. Cell Metab. 2018. 27: 977–987 e974.
82 Xia, H.,Wang,W.,Crespo, J.,Kryczek, I., Li,W.,Wei, S.,Bian, Z. et al., Sup-
pression of FIP200 and autophagy by tumor-derived lactate promotes
naive T cell apoptosis and affects tumor immunity. Sci. Immunol. 2017. 2:
eaan4631.
83 Haas, R., Smith, J., Rocher-Ros, V., Nadkarni, S., Montero-Melendez, T.,
D’Acquisto, F., Bland, E. J. et al., Lactate regulates metabolic and pro-
inflammatory circuits in control of T cell migration and effector func-
tions. PLoS Biol. 2015. 13: e1002202.
84 Ma, E. H., Bantug, G., Griss, T., Condotta, S., Johnson, R. M., Samborska,
B.,Mainolfi, N. et al., Serine is an essential metabolite for effector T cell
expansion. Cell Metab. 2017. 25: 345–357.
85 Swamy, M., Pathak, S., Grzes, K. M., Damerow, S., Sinclair, L. V., van
Aalten, D. M. and Cantrell, D. A., Glucose and glutamine fuel protein
O-GlcNAcylation to control T cell self-renewal and malignancy. Nat.
Immunol. 2016. 17: 712–720.
86 Loftus, R. M., Assmann, N., Kedia-Mehta, N., O’Brien, K. L., Garcia, A.,
Gillespie, C.,Hukelmann, J. L. et al., Amino acid-dependent cMyc expres-
sion is essential for NK cell metabolic and functional responses in mice.
Nat. Commun. 2018. 9: 2341.
87 Avgerinos, K. I., Spyrou, N., Mantzoros, C. S. and Dalamaga, M., Obe-
sity and cancer risk: Emerging biological mechanisms and perspectives.
Metabolism 2019. 92: 121–135.
88 Dyck, L. and Lynch, L., Cancer, obesity and immunometabolism - Con-
necting the dots. Cancer Lett. 2018. 417: 11–20.
89 Michelet, X., Dyck, L., Hogan, A., Loftus, R. M., Duquette, D., Wei, K.,
Beyaz, S. et al.,Metabolic reprogramming of natural killer cells in obesity
limits antitumor responses. Nat. Immunol. 2018. 19: 1330–1340.
90 Sukumar, M., Kishton, R. J. and Restifo, N. P., Metabolic reprograming of
anti-tumor immunity. Curr. Opin. Immunol. 2017. 46: 14–22.
91 Fletcher, M., Ramirez, M. E., Sierra, R. A., Raber, P., Thevenot, P., Al-
Khami, A. A., Sanchez-Pino, D. et al., l-Arginine depletion blunts anti-
tumor T-cell responses by inducing myeloid-derived suppressor cells.
Cancer Res. 2015. 75: 275–283.
92 Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T.,
Kogadeeva, M. et al., L-arginine modulates T cell metabolism and
enhances survival and anti-tumor activity. Cell 2016. 167: 829–842 e813.
93 Johnson, M. O., Wolf, M. M., Madden, M. Z., Andrejeva, G., Sugiura, A.,
Contreras, D. C., Maseda, D. et al., Distinct regulation of Th17 and Th1
cell differentiation by glutaminase-dependent metabolism. Cell 2018.
175: 1780–1795 e1719.
94 Munn, D. H. and Mellor, A. L., Indoleamine 2,3 dioxygenase and
metabolic control of immune responses. Trends Immunol. 2013. 34: 137–
143.
95 Jonescheit, H., Oberg, H. H., Gonnermann, D., Hermes, M., Sulaj, V.,
Peters, C., Kabelitz, D. et al., Influence of indoleamine-2,3-dioxygenase
and itsmetabolite kynurenine on gammadelta T cell cytotoxicity against
ductal pancreatic adenocarcinoma cells. Cells 2020. 9: 1140.
96 Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N.,
Karoly, E. D. et al., PD-1 alters T-cell metabolic reprogramming by
inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.
Nat. Commun. 2015. 6: 6692.
97 Parry, R.V.,Chemnitz, J.M.,Frauwirth,K.A.,Lanfranco,A. R.,Braunstein,
I.,Kobayashi, S. V., Linsley, P. S. et al., CTLA-4 and PD-1 receptors inhibit
T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005. 25: 9543–
9553.
98 Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J.,Wallweber, H. A., Sasmal,
D. K. et al., T cell costimulatory receptor CD28 is a primary target for
PD-1-mediated inhibition. Science 2017. 355: 1428–1433.
99 Klein Geltink, R. I., O’Sullivan, D., Corrado, M., Bremser, A., Buck, M. D.,
Buescher, J. M., Firat, E. et al., Mitochondrial Priming by CD28. Cell 2017.
171: 385–397 e311.
100 Menk, A. V., Scharping, N. E., Rivadeneira, D. B., Calderon, M. J.,
Watson, M. J., Dunstane, D., Watkins, S. C. et al., 4-1BB costimula-
tion induces T cell mitochondrial function and biogenesis enabling
cancer immunotherapeutic responses. J. Exp. Med. 2018. 215: 1091–
1100.
101 Yi, Y.,He, H.W.,Wang, J. X.,Cai, X. Y., Li, Y.W., Zhou, J.,Cheng, Y. F. et al.,
The functional impairment of HCC-infiltrating gammadelta T cells, par-
tially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent
manner. J. Hepatol. 2013. 58: 977–983.
102 Adams, E. J., Gu, S. and Luoma, A. M., Human gamma delta T cells: Evo-
lution and ligand recognition. Cell. Immunol. 2015. 296: 31–40.
103 Bonneville, M. and Scotet, E., Human Vgamma9Vdelta2 T cells: promis-
ing new leads for immunotherapy of infections and tumors. Curr. Opin.
Immunol. 2006. 18: 539–546.
104 Wu, Y., Kyle-Cezar, F., Woolf, R. T., Naceur-Lombardelli, C., Owen, J.,
Biswas, D., Lorenc, A. et al., An innate-like Vdelta1(+) gammadelta T
cell compartment in the human breast is associated with remission in
triple-negative breast cancer. Sci. Transl. Med. 2019. 11: eaax9364.
105 Patil, R. S., Shah, S. U., Shrikhande, S. V., Goel, M., Dikshit, R. P. and
Chiplunkar, S. V., IL17 producing gammadeltaT cells induce angiogene-
sis and are associated with poor survival in gallbladder cancer patients.
Int. J. Cancer 2016. 139: 869–881.
Abbreviations: γδ: gamma delta · ACT: adoptive cell therapy ·
DETC: dendritic epidermal γδ T cell · HFD: high-fat diet · IFN-
γ: interferon-gamma · IL-17: interleukin-17 · LN: lymph node ·
MCA: methylcholanthrene · MDSC: myeloid-derived suppressor
cell · OXPHOS: oxidative phosphorylation · SCENITH: single cell
metabolism by profiling translation inhibition · SPM: small peri-
toneal macrophage · TCR: T-cell receptor · TME: tumor microen-
vironment · VEGF: vascular endothelial growth factor
Full correspondence: Dr. Bruno Silva-Santos, Instituto de Medicina






Accepted article online: 14/11/2020
© 2020 The Authors. European Journal of Immunology published by
Wiley-VCH GmbH
www.eji-journal.eu
